Helen, why don't you take number one on guidance, and I'll take number two on Medicare Advantage, please. I think the government just gets caught up in their political agenda, in their calculations and what they're trying to do. And we've had the first really a bit of bad news, came from the CCX140 Phase II trial where the data just did not show efficacy that we were looking for in terms of treating Focal Segmental Glomerulosclerosis, which is basically a situation where you've got a part of your glomeruli do the filtration, they don't work. I think a bigger concern and just thinking our way through, it would be tax reform. Receive obituaries from the city or cities of your choice. Thank you, Rice. Send your deepest condolences with fresh flowers. In the Asia Pacific region, postponement of elective procedures due to the pandemic, impacted the Care Coordination business in Australia. And from today's perspective, we are not aware of any special item. And then second question, just on your guidance. So to the extent that those entity is also -- were incurring COVID-related expenses, excuse me, they would also benefit. But we are not doing so in a nervous or worried fashion. Gods Speed on your journey. Our operational strength continued despite the impact of COVID-19. So again, I say we are comfortable with where we sit and how we think this will unfold over time. I mean if that were to happen, there's a part of that population -- as you well know, people have the ability to get on at any age if they've got in-stage renal disease. So I think we'll have to work through that. and we come back to -- when we measure the way we look at this, a big piece of that unemployment in the U.S. is going to be people that are in the gig economy or they were not in a place or in a job situation where they had any type of group or company-sponsored health plan. And obviously, the closer Humacyte get to launch, the kind of the changes will continue to go through the P&L. As mentioned, we saw the pandemic continuing to spread globally. I'm just curious if you can help us sort of work through some of the sort of scenarios around that, that would be really helpful. Thank you, Helen. So we feel good about that. After corporate costs and cost allocation, this results in a 240 basis points improvement to the group margin. L.A.; San Diego; Dallas; Houston; Chicago; I think Miami, they've already made those decisions. I think we may see some trailing off of acute product. And then the Dialysis Products, we're still working very well in Eastern Europe and the Middle East and some of the African countries. you can now have memorial trees planted in a National Forest in memory of your loved one. Look, James, as far as guidance is concerned, I think it's how I answered the earlier question. As a result of the strong operating cash flow, free cash flow improved significantly year-over-year to more than €2.1 billion. Or do you feel that a lot of the headwinds that had impacted the business negatively are starting to dissipate a bit, and this is kind of operationally, the new normal in terms of what you can do in the business? Robert Powell (/ ˈ p aʊ ə l /; born 1 June 1944) is an English actor and voice actor, best known for the title roles in Mahler (1974) and Jesus of Nazareth (1977), and for his portrayal of secret agent Richard Hannay in The Thirty Nine Steps and its subsequent spinoff television series.. Robert was proud to serve his country in the United States Army. Robert Otis Powell (aka Bob, Bobby, Otis, Hut, Hook, Wingman) passed away peacefully on May 30, 2020 with his wife and children at his bedside. Particularly today, right? It's not always real clear to us what we're dealing with there. And now we're going to expand that an additional 100. No memorial events are currently scheduled. We shared a lot of good memories together and we will greatly miss him. Some believe it never left. I think on an EBIT level, it does get somewhat lumpy with how the costs hit the quarters. You may also light a … And then a question for Helen. Can you hear me? The margin increase in our dialysis business was 4.2 percentage points. Based on a strong underlying business performance, the increase was largely due to the recovery of COVID-19-related negative effects that we experienced in the first quarter, and our ongoing cost saving measures contributed to our ability to overcome this. So I think we're just going to see some shifts in gazing. Don't forget, we had a big hit last year for the ESCO charge that we took, which was €41 million. And we just have to be excruciatingly detailed and aggressive in our planning to try to work our way through them. So we'll have a little bit of time to work through that. Why don't I take hospitalization, and Helen, if you would, please, take the guidance? Moving to Slide 7. We had no support from exchange rates, and yet we achieved a 5% top line growth, and we'll share some of the details with you in due course of the presentation. There's our investments and the investment in Humacyte particularly, which is -- that valuation is driven by a function of discount rates and risk premiums. https://www.nytimes.com/2020/07/16/magazine/colin-powell-iraq-war.html But at this point in time, we are still seeing continued small improvements in our commercial mix. And I'm curious why it is so low and whether the minority interest holders did not benefit from the CARES Act. We are working on a value-based relationship in order to improve quality of care for our members.

But even without that, we would be at 3.1, which is still improved from the 3.3 that we saw last quarter. Thanks, Rice. And is that just the start of a longer-term program or is that where you think you'll kind of meet your ultimate needs in terms of home dialysis training? So we see the fourth quarter potentially looking just as intense as second quarter did. Special to USA TODAY ... Schreiber says many non-covered governmental workers are surprised to learn that they may experience in 2020 … But for them, where would we be? In addition, the pandemic caused an interruption in our routine medical visits and necessary hospitalizations for many patients with advanced CKD moving into end-stage renal disease and treatment. So on a Q1 to Q2 impact, it's neutral, and it's about €40 million of EBIT for both positive and negative between the quarters. So figure, 165 max, if we get everything done this year and an incremental 100. Veronika, I'll take both of those. It was an honor to know you sir . We are sad to announce that on September 16, 2020 we had to say goodbye to Robert Lewis Powell Sr. of King George, Virginia. A post shared by Bindi Irwin (@bindisueirwin) on Sep 22, 2020 at 4:33am PDT Sept. 22 (UPI) -- Bindi Irwin and her husband, Chandler Powell, say their unborn baby is a girl. Folks in that we've had history with, value-based care, which is the way I describe exactly what you were looking at, cost sharing and what do we do, that's value-based care in my mind. But we would hope that, that would recover as well in Q3. And also maybe if you have an indication what is left from CARES in terms of cost contribution for the second half, that would be helpful. We do expect, as usual, there'll be some small changes relative to adjusted inflations of that basket and things of that nature, ASP will have some impact. Rice, I had two questions. I think it's exactly accurate. Thank you, Emma. So we've had a long-running pilot on value-based care. So if you look in Asia Pacific, home in Asia is generally PD. I mean this is something that we can flex as we need to. There will be some element of critical care pay where we pulse our needs and our spend in that current hotspots that we are seeing in the United States. We've got some -- we're finishing up work in the factory, we're expanding capacity. The first is related to cash flow. So I think we just have to wait and see what's going to happen. Yes. Did you want -- yes, okay. Stay well, everyone. I know your follow-on question, Tom, will be, well, is it going to be another 100 next year, another 100? I think you recall from what we said in Q1 that we have to attest to this at a tax ID level. And lastly, when you look at the leverage ratios on the bottom left of the page, including IFRS 16, the leverage ratio sequentially improved from 3.3x net debt-to-EBITDA to a ratio of 2.8x. First one is just on the slowdown in same market treatment growth in the U.S. Calcimimetics will be included in the bundle next year and now we must wait until the fall to see what the final rule for 2021 will bring us. Love & blessings. I think that the Dialysis Product growth should continue.